Pharmacophore-based virtual screening and docking studies on Hsp90 inhibitors

Area of Science:

• Medicinal Chemistry
• Computational Chemistry
• Pharmacology

Background:

• Heat Shock Protein 90 (Hsp90) is a crucial therapeutic target for cancer treatment.
• Understanding the structural requirements for Hsp90 inhibition is vital for drug discovery.

Purpose of the Study:

• To develop a 3D-QSAR pharmacophore model to identify critical chemical features for Hsp90 inhibitory activity.
• To utilize the validated model for virtual screening and identify potential novel Hsp90 inhibitors.

Main Methods:

• A 3D-QSAR pharmacophore model (HypoGen) was developed using 61 known Hsp90 inhibitors.
• The model was validated using a test set of 30 compounds and confirmed essential features (HY, HBA, HBD).
• Virtual screening of Maybridge and NCI databases was performed using the validated model, followed by molecular docking.

Main Results:

• The best HypoGen model comprised five features: one hydrogen bond acceptor (HBA), one hydrogen bond donor (HBD), and three hydrophobic (HY) groups.
• The model demonstrated high correlation (r = 0.943) and low RMSD (0.751), with strong predictive power (R(2)pred = 0.805).
• Virtual screening identified five prioritized hit compounds with potential Hsp90 inhibitory activity based on docking scores.

Conclusions:

• The developed 3D-QSAR pharmacophore model effectively identifies essential features for Hsp90 inhibition.
• The model serves as a valuable tool for virtual screening to discover novel Hsp90-targeting anticancer agents.
• The identified lead compounds warrant further investigation as potential therapeutic candidates.